ChAd63-MVA-vectored blood-stage Malaria vaccines targeting MSP1 and AMA1: Assessment of efficacy against mosquito bite challenge in humans

Molecular Therapy

Volumn 20, Issue 12, 2012, Pages 2355-2368

  Sheehy, Susanne H ^a   Duncan, Christopher Ja ^a   Elias, Sean C ^a   Choudhary, Prateek ^a   Biswas, Sumi ^a   Halstead, Fenella D ^a   Collins, Katharine A ^a   Edwards, Nick J ^a   Douglas, Alexander D ^a   Anagnostou, Nicholas A ^a   Ewer, Katie J ^a   Havelock, Tom ^b,c   Mahungu, Tabitha ^d   Bliss, Carly M ^a   Miura, Kazutoyo ^e   Poulton, Ian D ^a   Lillie, Patrick J ^a   Antrobus, Richard D ^a   Berrie, Eleanor ^a   Moyle, Sarah ^a   Gantlett, Katherine ^a   Colloca, Stefano ^f,g   Cortese, Riccardo ^f,g   Long, Carole A ^e   Sinden, Robert E ^a,h   Gilbert, Sarah C ^a   Lawrie, Alison M ^a   Doherty, Tom ^d   Faust, Saul N ^b,c   Nicosia, Alfredo ^f,g,i   Hill, Adrian Vs ^a   Draper, Simon J ^a   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f NIAID/NIH ^*  (Italy)

^g CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

ⁱ UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; APICAL MEMBRANE ANTIGEN 1; IMMUNOGLOBULIN G ANTIBODY; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1;

ADENOVIRUS; ADULT; ANOPHELES STEPHENSI; ANTIBODY TITER; ARTICLE; BLOOD PARASITE; CELLULAR IMMUNITY; CHIMPANZEE ADENOVIRUS 63; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; FEMALE; GROWTH RATE; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOREACTIVITY; INFECTION PREVENTION; INSECT BITE; MALARIA FALCIPARUM; MALE; MODIFIED VACCINIA VIRUS ANKARA; MULTICENTER STUDY; ORTHOPOXVIRUS; PARASITE DEVELOPMENT; PARASITEMIA; PHASE 2 CLINICAL TRIAL; PHENOTYPE; VACCINATION;

CHIMPANZEE ADENOVIRUS; ORTHOPOXVIRUS; PLASMODIUM FALCIPARUM;

EID: 84870602529     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.223     Document Type: Article

References (50)

1. Murray, CJ, Rosenfeld, LC, Lim, SS, Andrews, KG, Foreman, KJ, Haring, D et al. (2012). Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 379: 413-431.
2. Agnandji, ST, Lell, B, Soulanoudjingar, SS, Fernandes, JF, Abossolo, BP, Conzelmann, C et al. (2011). First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 365: 1863-1875.
3. Duncan, CJ, Hill, AV and Ellis, RD (2012). Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy? Hum Vaccin Immunother 8: 706-714.
4. Bouharoun-Tayoun, H, Attanath, P, Sabchareon, A, Chongsuphajaisiddhi, T and Druilhe, P (1990). Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J Exp Med 172: 1633-1641.
5. Holder, AA (2009). The carboxy-terminus of merozoite surface protein 1: structure, specific antibodies and immunity to malaria. Parasitology 136: 1445-1456.
6. Remarque, EJ, Faber, BW, Kocken, CH and Thomas, AW (2008). Apical membrane antigen 1: a malaria vaccine candidate in review. Trends Parasitol 24: 74-84.
7. Dutta, S, Sullivan, JS, Grady, KK, Haynes, JD, Komisar, J, Batchelor, AH et al. (2009). High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model. PLoS ONE 4: e8138.
8. Lyon, JA, Angov, E, Fay, MP, Sullivan, JS, Girourd, AS, Robinson, SJ et al. (2008). Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses. PLoS ONE 3: e2830.
9. Thera, MA, Doumbo, OK, Coulibaly, D, Laurens, MB, Ouattara, A, Kone, AK et al. (2011). A field trial to assess a blood-stage malaria vaccine. N Engl J Med 365: 1004-1013.
10. Good, MF and Engwerda, C (2011). Defying malaria: Arming T cells to halt malaria. Nat Med 17: 49-51.
11. Joos, C, Marrama, L, Polson, HE, Corre, S, Diatta, AM, Diouf, B et al. (2010). Clinical protection from falciparum malaria correlates with neutrophil respiratory bursts induced by merozoites opsonized with human serum antibodies. PLoS ONE 5: e9871.
12. Walther, M, Woodruff, J, Edele, F, Jeffries, D, Tongren, JE, King, E et al. (2006). Innate immune responses to human malaria: heterogeneous cytokine responses to bloodstage Plasmodium falciparum correlate with parasitological and clinical outcomes. J Immunol 177: 5736-5745.
13. Belnoue, E, Voza, T, Costa, FT, Grüner, AC, Mauduit, M, Rosa, DS et al. (2008). Vaccination with live Plasmodium yoelii blood stage parasites under chloroquine cover induces cross-stage immunity against malaria liver stage. J Immunol 181: 8552-8558.
14. Draper, SJ, Moore, AC, Goodman, AL, Long, CA, Holder, AA, Gilbert, SC et al. (2008). Effective induction of high-titer antibodies by viral vector vaccines. Nat Med 14: 819-821.
15. Biswas, S, Dicks, MDJ, Long, CA, Remarque, EJ, Siani, L, Colloca, S et al. (2011). Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1. PLoS One 6: e20977.
16. .Goodman, AL, Epp, C, Moss, D, Holder, AA, Wilson, JM, Gao, GP et al. (2010). New candidate vaccines against blood-stage Plasmodium falciparum malaria: primeboost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1. Infect Immun 78: 4601-4612.
17. Draper, SJ, Biswas, S, Spencer, AJ, Remarque, EJ, Capone, S, Naddeo, M et al. (2010). Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines. J Immunol 185: 7583-7595.
18. Draper, SJ, Goodman, AL, Biswas, S, Forbes, EK, Moore, AC, Gilbert, SC et al. (2009). Recombinant viral vaccines expressing merozoite surface protein-1 induce antibodyand T cell-mediated multistage protection against malaria. Cell Host Microbe 5: 95-105.
19. Forbes, EK, Biswas, S, Collins, KA, Gilbert, SC, Hill, AV and Draper, SJ (2011). Combining liver- and blood-stage malaria viral-vectored vaccines: investigating mechanisms of CD8+ T cell interference. J Immunol 187: 3738-3750.
20. Biswas, S, Spencer, AJ, Forbes, EK, Gilbert, SC, Holder, AA, Hill, AV et al. (2012). Recombinant viral-vectored vaccines expressing Plasmodium chabaudi AS apical membrane antigen 1: mechanisms of vaccine-induced blood-stage protection. J Immunol 188: 5041-5053.
21. Sheehy, SH, Duncan, CJ, Elias, SC, Collins, KA, Ewer, KJ, Spencer, AJ et al. (2011). Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol Ther 19: 2269-2276.
22. Sheehy, SH, Duncan, CJ, Elias, SC, Biswas, S, Collins, KA, O'Hara, GA et al. (2012). Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS ONE 7: e31208.
23. O'Hara, GA, Duncan, CJ, Ewer, KJ, Collins, KA, Elias, SC, Halstead, FD et al. (2012). Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis 205: 772-781.
24. Barnes, E, Folgori, A, Capone, S, Swadling, L, Aston, S, Kurioka, A et al. (2012). Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 4: 115ra1.
25. Barouch, DH, Liu, J, Li, H, Maxfield, LF, Abbink, P, Lynch, DM et al. (2012). Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482: 89-93.
26. Good, MF, Xu, H, Wykes, M and Engwerda, CR (2005). Development and regulation of cell-mediated immune responses to the blood stages of malaria: implications for vaccine research. Annu Rev Immunol 23: 69-99.
27. Makobongo, MO, Riding, G, Xu, H, Hirunpetcharat, C, Keough, D, de Jersey, J et al. (2003). The purine salvage enzyme hypoxanthine guanine xanthine phosphoribosyl transferase is a major target antigen for cell-mediated immunity to malaria. Proc Natl Acad Sci USA 100: 2628-2633.
28. Epstein, JE, Rao, S, Williams, F, Freilich, D, Luke, T, Sedegah, M et al. (2007). Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update. J Infect Dis 196: 145-154.
29. Xu, H, Hodder, AN, Yan, H, Crewther, PE, Anders, RF and Good, MF (2000). CD4+ T cells acting independently of antibody contribute to protective immunity to Plasmodium chabaudi infection after apical membrane antigen 1 immunization. J Immunol 165: 389-396.
30. Riley, EM, Allen, SJ, Wheeler, JG, Blackman, MJ, Bennett, S, Takacs, B et al. (1992). Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (PfMSP1) of Plasmodium falciparum are associated with reduced malaria morbidity. Parasite Immunol 14: 321-337.
31. Pombo, DJ, Lawrence, G, Hirunpetcharat, C, Rzepczyk, C, Bryden, M, Cloonan, N et al. (2002). Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet 360: 610-617.
32. Pichyangkul, S, Tongtawe, P, Kum-Arb, U, Yongvanitchit, K, Gettayacamin, M, Hollingdale, MR et al. (2009). Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys. Vaccine 28: 452-462.
33. Stowers, AW, Kennedy, MC, Keegan, BP, Saul, A, Long, CA and Miller, LH (2002). Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria. Infect Immun 70: 6961-6967.
34. Sedegah, M, Tamminga, C, McGrath, S, House, B, Ganeshan, H, Lejano, J et al. (2011). Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults. PLoS ONE 6: e24586.
35. Saul, A, Lawrence, G, Smillie, A, Rzepczyk, CM, Reed, C, Taylor, D et al. (1999). Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant. Vaccine 17: 3145-3159.
36. Porter, DW, Thompson, FM, Berthoud, TK, Hutchings, CL, Andrews, L, Biswas, S et al. (2011). A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine. Vaccine 29: 7514-7522.
37. .Szarfman, A, Walliker, D, McBride, JS, Lyon, JA, Quakyi, IA and Carter, R (1988). Allelic forms of gp195, a major blood-stage antigen of Plasmodium falciparum, are expressed in liver stages. J Exp Med 167: 231-236.
38. .Bejon, P, Andrews, L, Andersen, RF, Dunachie, S, Webster, D, Walther, M et al. (2005). Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. J Infect Dis 191: 619-626.
39. .Silvie, O, Franetich, JF, Charrin, S, Mueller, MS, Siau, A, Bodescot, M et al. (2004). A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites. J Biol Chem 279: 9490-9496.
40. .Bodescot, M, Silvie, O, Siau, A, Refour, P, Pino, P, Franetich, JF et al. (2004). Transcription status of vaccine candidate genes of Plasmodium falciparum during the hepatic phase of its life cycle. Parasitol Res 92: 449-452.
41. .Miura, K, Zhou, H, Diouf, A, Moretz, SE, Fay, MP, Miller, LH et al. (2009). Antiapical- membrane-antigen-1 antibody is more effective than anti-42-kilodaltonmerozoite- surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay. Clin Vaccine Immunol 16: 963-968.
42. .Duncan, CJ and Draper, SJ (2012). Controlled human blood stage malaria infection: current status and potential applications. Am J Trop Med Hyg 86: 561-565.
43. .Spring, MD, Cummings, JF, Ockenhouse, CF, Dutta, S, Reidler, R, Angov, E et al. (2009). Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. PLoS ONE 4: e5254.
44. .de Cassan, SC, Forbes, EK, Douglas, AD, Milicic, A, Singh, B, Gupta, P et al. (2011). The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus. J Immunol 187: 2602-2616.
45. .Douglas, AD, Williams, AR, Illingworth, JJ, Kamuyu, G, Biswas, S, Goodman, AL et al. (2011). The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nat Commun 2: 601.
46. .Thompson, FM, Porter, DW, Okitsu, SL, Westerfeld, N, Vogel, D, Todryk, S et al. (2008). Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial. PLoS ONE 3: e1493.
47. .Andrews, L, Andersen, RF, Webster, D, Dunachie, S, Walther, RM, Bejon, P et al. (2005). Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials. Am J Trop Med Hyg 73: 191-198.
48. .Hermsen, CC, Telgt, DS, Linders, EH, van de Locht, LA, Eling, WM, Mensink, EJ et al. (2001). Detection of Plasmodium falciparum malaria parasites in vivo by real-time quantitative PCR. Mol Biochem Parasitol 118: 247-251.
49. Wang, CW, Hermsen, CC, Sauerwein, RW, Arnot, DE, Theander, TG and Lavstsen, T (2009). The Plasmodium falciparum var gene transcription strategy at the onset of blood stage infection in a human volunteer. Parasitol Int 58: 478-480.
50. .Hermsen, CC, de Vlas, SJ, van Gemert, GJ, Telgt, DS, Verhage, DF and Sauerwein, RW (2004). Testing vaccines in human experimental malaria: statistical analysis of parasitemia measured by a quantitative real-time polymerase chain reaction. Am J Trop Med Hyg 71: 196-201.